Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CAPR vs DMAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Captures Overall Composite Edge (46.3 HOLD vs 28.0 SELL), While CAPR Leads 4–1 on Growth & Valuation Pillars

DMAC Overall Winner 6-Pillar Tally: CAPR 4 – 1 DMAC (1 Tie) Matrix Metrics: CAPR 4 – 4 DMAC

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Capricor Therapeutics Inc (CAPR) on higher Unified Composite conviction (46.3/100 HOLD vs. 28.0/100 SELL) after splitting the core matrix 4–4 (led by Balance Sheet & Cash Flow), while CAPR wins 4–1 across the 6-pillar growth and valuation breakdown. CAPR trades at $8.47 (78.7x Forward P/E, 0.0% operating margin) versus DMAC at $8.41 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. CAPR 28.0/100 SELL) and 1.74β · 98% Vol risk profile, whereas CAPR leads top-line expansion (-7.9% YoY revenue growth, 0.38x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAPR vs DMAC
CAPR NASDAQ
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.0 · SMA20: $9.24 · SMA50: $8.24

6-Pillar Scorecard Institutional Category Breakdown (CAPR 4 – 1 DMAC)

Columns: Metric · CAPR · DMAC
1. Valuation Multiples CAPR
Forward P/E 78.7x N/M
Trailing P/E 78.7x N/M
PEG Ratio 0.38x N/M
EV / Revenue 57.8x N/M
2. Growth & Scale CAPR
Revenue Growth (YoY) -7.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M N/A
Market Cap $595.4M $503.1M
3. Profitability & Quality CAPR
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -100.5% -114.6%
4. Balance Sheet & Cash Flow DMAC
Cash Generation (TTM) -$146M -$32M
Cash Flow Margin N/A N/A
Net Cash / Leverage $48M Net Debt (0.44x D/E) $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 637.1% (89th %ile) 106.3% (14th %ile)
Put/Call OI Skew 1.57x (Put-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAPR (4) vs DMAC (4)
Institutional Metric CAPR DMAC Criterion Row Edge
Market Capitalization
Scale
$595.4M $503.1M Larger Scale CAPR
Trailing P/E Ratio
Valuation
78.7x N/M Lower Multiple CAPR
Forward P/E Ratio
Valuation
78.7x N/M Lower Multiple CAPR
Revenue Growth (YoY)
Growth
-7.9% +0.0% Higher Growth DMAC
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-100.5% -114.6% Higher ROE CAPR
52-Week Range Position
Momentum
15% ($3–$40) 55% ($5–$11) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
1.52β · 152% Vol 1.74β · 98% Vol Lower Realized Risk DMAC
Unified Institutional Score
Composite Signal
28.0 / 100 (SELL) 46.3 / 100 (HOLD) Higher Composite DMAC
Trailing 12M Revenue (USD)
Operating Scale
$11M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.38x PEG · 57.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$146M ($48M Net Debt (0.44x D/E)) -$32M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +15.07 pp
CAPR: +26.23% · DMAC: +11.16%
3M Horizon DMAC +7.68 pp
CAPR: +19.63% · DMAC: +27.31%
6M Horizon DMAC +109.44 pp
CAPR: -70.58% · DMAC: +38.86%
1Y Horizon DMAC +8.47 pp
CAPR: +46.79% · DMAC: +55.26%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CAPR Revenue DMAC Revenue CAPR Op. Margin DMAC Op. Margin Margin Leader
FY2017 $0M N/A -482.4% N/A CAPR
FY2018 $0M $0M -917.0% -1352.2% CAPR
FY2019 $0M N/A -769.5% N/A CAPR
FY2020 $0M N/A -4412.6% N/A CAPR
FY2021 $0M N/A -8549.9% N/A CAPR
FY2022 $0M N/A -1163.9% N/A CAPR
FY2023 $30M N/A -95.6% N/A CAPR
FY2024 $20M N/A -191.1% N/A CAPR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CAPR vs DMAC Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Capricor Therapeutics Inc (CAPR) on higher Unified Composite conviction (46.3/100 HOLD vs. 28.0/100 SELL) after splitting the core matrix 4–4 (led by Balance Sheet & Cash Flow), while CAPR wins 4–1 across the 6-pillar growth and valuation breakdown. CAPR trades at $8.47 (78.7x Forward P/E, 0.0% operating margin) versus DMAC at $8.41 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. CAPR 28.0/100 SELL) and 1.74β · 98% Vol risk profile, whereas CAPR leads top-line expansion (-7.9% YoY revenue growth, 0.38x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

CAPR leads the Growth & Scale pillar: CAPR posts -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2024), CAPR cumulative revenue shifted -33.3% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, CAPR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.

CAPR screens cheaper on headline valuation multiples. CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAPR (-100.5% ROE) versus DMAC (-114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.